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2172ReplyEthnic Diversity and
Immunological Barriers
in Heart TransplantationWe appreciate the interest shown by Dr. Deutsch and colleagues in
our work (1) and their thoughtful comments regarding outcomes
after heart transplantation (HT) as a function of race, panel reactive
antibody (PRA) burden, and sensitization. We agree that existing
data suggest the superiority of tacrolimus-based immunosuppres-
sive regimens, particularly in black patients (2), with the proviso
that blacks often require higher tacrolimus doses to reach thera-
peutic trough concentrations (3,4). Importantly, a recent analysis
from the United Network for Organ Sharing (UNOS) database
shows that a higher proportion of black HT recipients were
receiving tacrolimus therapy than whites in recent years (5). We did
not investigate differences in the use of various induction strategies,
but previous studies have shown that induction immunosuppres-
sion using lymphocytolytic agents in the early perioperative period
was associated with a survival beneﬁt in younger black patients
with 4 human leukocyte antigen (HLA) mismatches (6).
Dr. Deutsch and colleagues also correctly noted the insensitivity
of standard Centers for Disease Control and Prevention (CDC)-
based PRA testing compared to newer solid-phase or microsphere-
based assays that have been increasingly used since the mid-1990s
(7). Speciﬁc information regarding the technique used for
HLA antibody detection was however not available in the UNOS
database. To partially circumvent this issue, we limited our analysis
to transplantations that were performed after 2000, hoping
to capture the PRA results that were largely based on newer
HLA platforms. Recent consensus guidelines in this regard pub-
lished by the Transplantation Society provide state-of-the-art
guidance in the clinical application of newer methods for HLA
antibody detection when used in conjunction with conventional
methods (8).
Clinical studies that further investigate the results of our study
incorporating speciﬁc information on the various induction and
maintenance immunosuppressive regimens used and the immu-
nologic assays performed for assessment of sensitization status will
be of great interest.*Alanna A. Morris, MD
Javed Butler, MD, MPH
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Hemorrhage on
Magnetic Resonance
Imaging and Recurrent
Cerebrovascular EventsWe read with interest the recent report by Saam et al. (1) describing
the predictive value of magnetic resonance imaging–detected carotid
plaque hemorrhage for cerebrovascular events. They undertook a
meta-analysis of the published research through September 2012
assuming a constant event rate during follow-up to derive an esti-
mated hazard ratio for magnetic resonance imaging–detected carotid
plaque hemorrhage of 5.69 (95% conﬁdence interval: 2.98 to 10.87).
Unfortunately, the investigators missed our most recent work (2),
which included a meta-analysis and presented new combined data
from 3 previous studies (3–5) with increased length of follow-up.
We derived a broadly similar conclusion but preferred to report
the odds ratio, because the assumption of a constant event rate is
unlikely to be true. We found no signiﬁcant heterogeneity between
the studies included (p ¼ 0.26, I2 ¼ 22.3%). The “trim and ﬁll”
method (6) was applied to calculate the number of studies that
would be required to return the plot to “symmetry” and remove
publication bias and to provide a revised estimated odds ratio.
We also note that an assumption was made by the investigators
to treat the results from Kume et al. (7) as asymptomatic, despite
the investigators’ acknowledging that almost one third were
symptomatic. It would seem, without further data from Kume
et al.’s study, that these results should only be included in a com-
bined meta-analysis for the symptomatic and asymptomatic carotid
arteries and should be excluded from the meta-regression.
Repeating the meta-analysis including the data from Kume et al.,
we found an odds ratio at 7.87 (95% conﬁdence interval: 4.7 to 13),
but no heterogeneity. Whether or not symptom status affects the
relative risk remains unclear, as only 2 studies reported on
asymptomatic patients only.
